Little Green Pharma (ASX:LGP) Beta: -0.2872 (As of Jun. 26, 2026)


What is Little Green Pharma Beta?

Little Green Pharma ASX:LGP Beta is -0.2872 as of Jun. 26, 2026. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Little Green Pharma's Beta is -0.2872.

Little Green Pharma  (ASX:LGP) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Little Green Pharma Beta Related Terms

Little Green Pharma Beta Historical Data

* Premium members only.

The historical data trend for Little Green Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma Beta Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial 0.00 2.11 1.28 0.81 -0.44

Little Green Pharma Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.27 0.81 -0.74 -0.44

ASX:LGP vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Little Green Pharma Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's Beta distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's Beta falls into.


Little Green Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2872 mean?
Little Green Pharma (ASX:LGP) has a Beta of -0.2872 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Little Green Pharma and its competitors.
Is Little Green Pharma's Beta too high?
Little Green Pharma's current Beta is -0.2872.
How does Little Green Pharma's Beta compare to ZTS?
Little Green Pharma's Beta of -0.2872 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Little Green Pharma and its competitors. Little Green Pharma's current Beta is -0.2872. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.06 — trading 62.4% below its estimated fair value. The current Beta is -0.2872. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current Beta is -0.2872 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Little Green Pharma Business Description

Address 13A Bedbrook Place, Shenton Park, West Perth, Perth, WA, AUS, 6008
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).